Core Viewpoint - The company, Shanghai Rongtai Health Technology Co., Ltd., has announced its expected daily related transactions for the year 2026, which will not require shareholder approval and are deemed to not affect the company's independence or harm shareholder interests [2][3][4]. Group 1: Daily Related Transactions Overview - The board of directors approved the expected daily related transactions for 2026 on February 6, 2026, with a unanimous vote of 6 in favor and no abstentions or oppositions [3][4]. - Independent directors reviewed and approved the proposal, confirming that the expected transactions are necessary for daily operations and comply with market pricing principles [3][4]. - The audit committee also endorsed the proposal, stating that the transactions align with the interests of the company and its shareholders, ensuring no impact on the company's independence [4]. Group 2: Expected Transaction Amounts and Categories - The total expected amount for daily related transactions in 2026 is 69.70 million yuan (approximately 6,970.27 thousand yuan) [6]. - The transactions are based on market prices and are structured to ensure fairness and transparency, with contracts already signed with related parties for the year [8]. Group 3: Related Parties and Transaction Purpose - The related parties involved include Jiaxing Ouyuan Motor Co., Ltd. and Suzhou Shangse Metal Products Co., Ltd., both of which are operational and have strong performance records [8]. - The transactions are essential for the company's normal business operations and are expected to facilitate the execution of daily business activities without compromising the interests of shareholders [8].

Group 1 - Company Rongtai Health announced the convening of its fifth board meeting on February 6, 2026, in Shanghai, where it reviewed the proposal regarding expected annual related party transactions for 2026 [1] - The meeting was held in a hybrid format, combining in-person attendance and remote voting [1] Group 2 - The article also touches on the legality of personal stock trading by fund managers, revealing unexpected insights from several leading public funds [1]

万和证券股份有限公司 关于上海荣泰健康科技股份有限公司 2026 年度预计日常关联交易的核查意见 万和证券股份有限公司（以下简称"万和证券"或"保荐机构")作为上海 荣泰健康科技股份有限公司（以下简称"荣泰健康""上市公司"或"公司"）公 开发行可转换公司债券的保荐机构,根据《证券发行上市保荐业务管理办法》《上 海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号— —规范运作》《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等 有关规定,经审慎核查,就荣泰健康 2026年度预计日常关联交易所涉及的事项, 发表核查意见如下: 一、关联方介绍和关联关系 (一)关联方的基本情况 | 公司名称 | 嘉兴瓯源电机股份有限公司 | | --- | --- | | 统一社会信用代码 | 91330421757079929K | | 成立日期 | 2003年12月3日 | | 注册资本 | 307.69 万元人民币 | | 公司类型 | 股份有限公司(非上市、自然人投资或控股) | | 法定代表人 | 李暹强 | | 調慶庆 | 李逞强持股 57.85%，公司持股 35.00%，李志元持股 ...

关于预计公司 2026 年年度日常关联交易的公告 证券代码：603579 证券简称：荣泰健康 公告编号：2026-007 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要提示： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 上海荣泰健康科技股份有限公司 2026 年 2 月 6 日，上海荣泰健康科技股份有限公司（以下简称"公司"）召 开第五届董事会第六次会议，以 6 票赞成、0 票弃权、0 票反对的表决结果审议 通过了《关于预计公司 2026 年年度日常关联交易的议案》，对公司及子公司 2026 年度将发生的日常关联交易进行了预计，关联董事林光荣、林琪、王军良回避表 决。本议案无需提交公司股东会审议。 2026 年 2 月 6 日，公司召开 2026 年第二次独立董事专门会议对该议案进行 了审议，全体独立董事审议通过本议案，独立董事认为：公司与关联方之间预计 在 2026 年发生的日常关联交易均为公司日常生产经营活动所需，预计规模符合 公司经营计划和发展需要，交易价格参照市场价格协商确定，遵循了公平、公开、 ...

证券代码：603579 证券简称：荣泰健康 公告编号：2026-006 上海荣泰健康科技股份有限公司 第五届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 上海荣泰健康科技股份有限公司（以下简称"公司"）第五届董事会第六次 会议于 2026 年 2 月 6 日在上海市青浦区徐泾镇高光路 169 弄虹桥时代广场荣泰 大厦公司会议室以现场加通讯表决方式召开。会议通知和材料已于 2026 年 2 月 3 日以现场送达、电话或电子邮件等方式发出。本次会议由董事长林光荣先生主 持，会议应参加董事 9 人，实际参加董事 9 人。公司高级管理人员列席了会议。 本次会议的召集、召开程序符合《中华人民共和国公司法》等有关法律、法规、 《上海荣泰健康科技股份有限公司章程》（以下简称"《公司章程》"）的规定， 会议决议合法、有效。 授信额度：综合授信贰亿元人民币 借款时间：自董事会审议通过之日起至 2025 年年度股东会召开之日止 二、董事会会议审议情况 1、审议通过《关于预计公司 2026 年年度 ...

证券代码：603579 证券简称：荣泰健康 公告编号：2026-005 上海荣泰健康科技股份有限公司 关于使用闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已履行及拟履行的审议程序：上海荣泰健康科技股份有限公司（以下简 称"公司"）于 2025 年 4 月 23 日召开第四届董事会第二十一次会议、第四届监 事会第十六次会议，于 2025 年 5 月 14 日召开 2024 年年度股东大会，分别审议 通过了《关于公司 2025 年度使用可转债闲置募集资金进行现金管理的议案》，同 意公司及子公司使用最高不超过人民币 4.5 亿元的公开发行可转换公司债券（以 下简称"可转债"）闲置募集资金适时投资安全性高、流动性好、低风险的理财 产品或结构性存款，授权期限为自公司 2024 年年度股东大会审议通过之日起 12 个月内。在上述额度及授权期限内，资金可由公司、公司全资子公司共同滚动使 用。具体内容详见公司于 2025 年 4 月 24 日披露的《上海荣泰健康科技股份有限 公司关于使用可转 ...

Core Viewpoint - The other home appliance sector experienced a rise of 1.02% on February 4, with Rongtai Health leading the gains. The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1]. Group 1: Market Performance - The closing price and percentage change for key stocks in the other home appliance sector are as follows: - Rongtai Health: Closed at 24.71, up 1.31% with a trading volume of 46,500 shares and a transaction value of 114 million yuan [1]. - Qijiahua: Closed at 7.05, up 1.15% with a trading volume of 157,900 shares and a transaction value of 111 million yuan [1]. - Rongjie Health: Closed at 5.14, up 0.59% with a trading volume of 165,100 shares and a transaction value of 84.52 million yuan [1]. Group 2: Capital Flow - The net capital flow in the other home appliance sector on that day showed: - A net inflow of 10.30 million yuan from main funds, while retail funds experienced a net outflow of 7.32 million yuan [1]. - Rongtai Health had a main fund net inflow of 12.95 million yuan, accounting for 11.32% of its total, while retail funds saw a net outflow of 14.31 million yuan [1]. - Rongjie Health had a minor main fund net inflow of 270,400 yuan, while retail funds had a net outflow of 359,400 yuan [1]. - Qijiahua experienced a net outflow of 2.93 million yuan from main funds, but a net inflow of 7.35 million yuan from retail funds [1].

Core Viewpoint - The other home appliance sector experienced a 1.2% increase on February 3, with Rongjie Health leading the gains. The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1]. Group 1: Stock Performance - Rongjie Health (300247) closed at 5.11, with a rise of 2.20% and a trading volume of 176,900 shares, amounting to a transaction value of approximately 89.89 million yuan [1]. - Rongtai Health (603579) closed at 24.39, increasing by 1.54% with a trading volume of 27,300 shares, resulting in a transaction value of about 66.42 million yuan [1]. - Aojiahua (002614) closed at 6.97, up by 1.16% with a trading volume of 170,100 shares, leading to a transaction value of around 118 million yuan [1]. Group 2: Capital Flow - The other home appliance sector saw a net outflow of 7.92 million yuan from main funds, while retail funds experienced a net inflow of 0.10 million yuan [1]. - Rongtai Health had a net inflow of 1.14 million yuan from retail funds, but a net outflow of 1.56 million yuan from main funds, reflecting a decrease of 2.35% [1]. - Aojiahua experienced a net outflow of 0.94 million yuan from main funds, with a net inflow of 3.09 million yuan from retail funds, showing a decrease of 2.55% [1]. - Rongjie Health faced a significant net outflow of 8.24 million yuan from main funds, despite a net inflow of 3.58 million yuan from retail funds, indicating a decrease of 9.17% [1].

Core Viewpoint - Shanghai Rongtai Health Technology Co., Ltd. has decided to change the purpose of its repurchased shares to cancellation and reduce its registered capital, which will not significantly impact the company's financial status or operational results [2][8]. Group 1: Share Repurchase Overview - The company approved a share repurchase plan on November 2, 2023, with a total fund of no less than RMB 50 million and no more than RMB 100 million, at a price not exceeding RMB 33 per share [3]. - The repurchase was executed starting November 8, 2023, and by November 30, 2023, the company had repurchased a total of 2,306,200 shares, accounting for 1.6594% of the total share capital at an average price of RMB 21.68 per share, totaling RMB 50,000,683 [4]. Group 2: Cancellation of Repurchased Shares - The company plans to cancel 2,303,200 shares, which represents 1.13% of the total share capital before cancellation, reducing the total share capital from 203,355,564 shares to 201,052,364 shares [2][6]. - The cancellation process is scheduled to be completed by February 3, 2026, and complies with relevant legal requirements [7]. Group 3: Impact on Company Structure - Following the cancellation, the company's shareholding structure will remain compliant with listing conditions, and the proportion of shares held by major shareholders will increase without crossing the 5% or 1% thresholds [7]. - The cancellation will not adversely affect the company's debt repayment ability or ongoing operational capacity, nor will it harm the interests of the company and its shareholders [8]. Group 4: Future Arrangements - After the cancellation of shares, the company will proceed with necessary changes in business registration and articles of association, ensuring timely information disclosure as per legal regulations [8].

关于注销回购股份的实施公告 证券代码：603579 证券简称：荣泰健康 公告编号：2026-004 上海荣泰健康科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海荣泰健康科技股份有限公司（以下简称"公司"）于 2025 年 11 月 28 日、2025 年 12 月 17 日分别召开第五届董事会第三次会议、2025 年第三次临 时股东会审议通过了《关于变更公司 2023 年回购股份用途暨注销回购股份、变 更注册资本及修订<公司章程>的议案》，同意将 2023 年回购股份的用途变更为 注销并减少公司注册资本，本次注销的股份为存放于公司回购专用证券账户的 2,303,200 股，占注销前公司总股本的 1.13%。本次注销完成后，公司总股本将 由 203,355,564 股变更为 201,052,364 股，注册资本将由 203,355,564 元变更为 201,052,364 元。 本次回购股份注销事宜计划于 2026 年 2 月 3 日办理完成，本次回购股份 注销手续符合法律法规相关要求。 一 ...